Table 2. Clinicopathologic and treatment characteristics in patients who underwent therapeutic total gastrectomy for gastric cancer.
| Therapeutic Total Gastrectomy | All patients (n=40) n or median (% or range) | Hand-sewn anastomosis (n=22) n or median (% or range) | Modified Orringer anastomosis (n=18) n or median (% or range) |
|---|---|---|---|
|
| |||
| Age (years) | 67 (40-92) | 67 (40-82) | 68 (42-92) |
|
| |||
| Gender | |||
| Male | 22 (55.0) | 10 (45.5) | 12 (66.7) |
| Female | 18 (45.0) | 12 (54.5) | 6 (33.3) |
|
| |||
| Body mass index | 25.8 (17.3-42.1) | 25.5 (17.3-42.1) | 27.1 (20.8-34.0) |
|
| |||
| Gastrointestinal symptoms at presentationa | |||
| Abdominal pain or discomfort | 20 (50.0) | 11 (50.0) | 9 (50.0) |
| Nausea or vomiting | 18 (45.0) | 11 (50.0) | 7 (38.9) |
| Dyspepsia or heartburn | 5 (12.5) | 4 (18.2) | 1 (5.6) |
| Dysphagia | 4 (10.0) | 2 (9.1) | 2 (11.1) |
| Gastrointestinal bleed / Microcytic anemia | 9 (22.5) | 5(22.7) | 4 (22.2) |
| None | 1 (2.5) | 1 (4.5) | 0 (0.0) |
|
| |||
| Family history | |||
| Gastric cancer | 5 (12.5) | 4 (18.2) | 1 (5.6) |
| Breast cancer | 9 (22.5) | 5 (22.7) | 4 (22.2) |
|
| |||
| Neoadjuvant treatment | |||
| Chemotherapy | 17 (42.5) | 11 (50.0) | 6 (33.3) |
| Chemoradiation therapy | 3 (7.5) | 1 (4.5) | 2 (11.1) |
|
| |||
| Adjuvant treatment | |||
| Chemotherapy | 13 (32.5) | 8 (36.4) | 5 (27.8) |
| Chemoradiation therapy | 8 (20.0) | 6 (27.3) | 2 (11.1) |
|
| |||
| Operative time (minutes) | 266 (187-485) | 301 (224-485) | 242 (187-451) |
|
| |||
| Estimated intraoperative blood loss (milliliters) | 400 (100-1300) | 400 (250-1300) | 300 (100-1000) |
|
| |||
| Adjacent organ resectiona | |||
| Distal pancreatectomy | 3 (7.5) | 2 (9.1) | 1 (5.6) |
| Splenectomy | 12 (30.0) | 11 (50.0) | 3 (16.7) |
|
| |||
| Length of stay (days) | 9 (5-24) | 9.5 (5-24) | 8 (5-14) |
|
| |||
| Anastomotic leak | |||
| Radiographic | 3 (7.5) | 2 (9.1) | 1 (5.6) |
| Clinical | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
| |||
| Anastomotic stricture | 1 (2.5) | 0 (0.0) | 1 (5.6) |
|
| |||
| 30-day morbidity | 13 (32.5) | 9 (40.9) | 4 (22.2) |
|
| |||
| 30-day mortality | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|
| |||
| Weight loss (nadir % from baseline) | 17.3 (3.5-32.6) | 15.8 (6.3-29.6) | 18.6 (3.5-32.6) |
|
| |||
| Lauren histologic type | |||
| Intestinal | 12 (30.0) | 2 (9.1) | 10 (55.6) |
| Diffuse | 16 (40.0) | 13 (59.1) | 3 (16.7) |
| Mixed | 3 (7.5) | 0 (0.0) | 3 (16.7) |
| Unspecified | 9 (22.5) | 7 (31.8) | 2 (11.1) |
|
| |||
| Pathologic TNM stageb | |||
| Stage 0 | 3 (7.5) | 2 (9.1) | 1 (5.6) |
| Stage I | 10 (25.0) | 4 (18.2) | 6 (33.3) |
| Stage II | 10 (25.0) | 7 (31.8) | 3 (16.7) |
| Stage III | 17 (42.5) | 9 (40.9) | 8 (44.4) |
|
| |||
| Lymph nodes resected (n) | 39 (9-94) | 37 (9-83) | 39 (15-94) |
a
Categories not mutually exclusive
b
American Joint Committee on Cancer, 7th edition